Skip to main content
. 2017 Sep 16;8(59):99801–99815. doi: 10.18632/oncotarget.21068

Figure 2. Number of TAMs and SOX9 expression are correlated with patient outcomes.

Figure 2

(A) Immunohistochemistry of human NSCLC tumor tissues. CD163 and SOX9 staining intensities are shown. (B) Infiltration of CD163+ TAMs was increased in the high SOX9 expression group. (C) Overall and disease-free survival in NSCLC patients with high or low CD163 and SOX9 expression were examined. High expression of either CD163 or SOX9 was correlated with lower survival. Patients with high expression of both CD163 and SOX9 had shorter OS and DFS than those with high expression of either CD163 or SOX9. ***p < 0.01, mean ± SEM.